Molecular and Functional Defects in Kidneys of Mice Lacking Collagen α3(IV): Implications for Alport Syndrome

Jeffrey H. Miner and Joshua R. Sanes
Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri, 63110

Abstract. Collagen IV is a major structural component of all basal laminae (BLs). Six collagen IV α chains are present in mammals; α1 and α2(IV) are broadly expressed in embryos and adults, whereas α3–6(IV) are restricted to a defined subset of BLs. In the glomerular BL of the kidney, the α1 and α2(IV) chains are replaced by the α3–5(IV) chains as development proceeds. In humans, mutation of the collagen α3, α4, or α5(IV) chain genes results in a delayed onset renal disease called Alport syndrome. We show here that mice lacking collagen α3(IV) display a renal phenotype strikingly similar to Alport syndrome: decreased glomerular filtration (leading to uremia), compromised glomerular integrity (leading to proteinuria), structural changes in glomerular BL, and glomerulonephritis. Interestingly, numerous changes in the molecular composition of glomerular BL precede the onset of renal dysfunction; these include loss of collagens α4 and α5(IV), retention of collagen α1/2(IV), appearance of fibronectin and collagen VI, and increased levels of perlecain. We suggest that these alterations contribute, along with loss of collagen IV isoforms per se, to renal pathology.
binant α3-5(IV) fragments. Using these reagents, we showed that the distribution of the α1-5(IV) chains in mice is similar (but not identical) to that in humans (Miner and Sanes, 1994). Here, we describe the generation and characterization of mutant mice deficient in collagen α3(IV). We document hereditary glomerulonephritis in these mice and show that fundamental alterations in the composition of renal BLs precede detectable renal pathology. Thus, alterations in matrix composition resulting from the absence of collagen α3(IV) may influence the pathogenesis of Alport syndrome.

Materials and Methods

Generation of Mutant Mice

A λ clone containing the 3′ end of the Col4α3 gene was obtained by probing a 129sv mouse genomic library (Stratagene, La Jolla, CA) with a previously described collagen α3(IV) cDNA (Miner and Sanes, 1994). The targeting vector (see Fig. 1 a) replaced two consecutive AvrII fragments of Col4α3, which contain the first three NCI domain exons, with a neo cassette from the vector pPNT (Tytubeicz et al., 1991). The mutated gene was transferred to R1 ES cells (Nagy et al., 1993) by electroporation, and homologous recombinants were isolated by double selection with G418 (400 μg/ml) and 1,2'-deoxy-2'-fluoro-13D-arabino furanosyl] 5' iodo uracil (FIAU) (0.27 μM). The targeting frequency was 1 in 17. Chimeras from three independently derived ES clones gave rise to heterozygous and then homozygous mutants. The phenotypes of the three lines were indistinguishable, and results from all three have been combined for presentation here.

Molecular Analyses

For Southern analysis, genomic DNA from adult tail or liver was digested with PstI and probed with a 32P-labeled BamHI fragment of the Col4α3 genomic clone. The probe lies outside the genomic sequences in the targeting vector (Fig. 1 a), and thereby provides a stringent test of homologous recombination.

RNA protection analysis was performed using probes and methods described (Miner and Sanes, 1994). Based on the assumption that the abundance of EF1α RNA varies little among tissues or with age, the level of this RNA was assayed in each sample and used to correct for possible variation in RNA amounts or purity. Relative RNA levels were determined by scanning laser densitometry of autoradiograms using an LKB Ultrascan (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ).

Samples of blood and urine were collected from deeply anesthetized mice immediately before sacrifice. Total urinary protein was assayed with a Cobas Mira Plus analyzer (Roche, Somerville, NJ), and creatinine and urea nitrogen in serum and urine were measured with a Cobas Mira Plus analyzer (Roche, Somerville, NJ). Total urinary protein was assayed with Cobas Mira Plus analyzer (Roche, Somerville, NJ), and creatinine and urea nitrogen in serum and urine were measured with a Cobas Mira Plus analyzer (Roche, Somerville, NJ). Levels of creatinine and urea nitrogen were assayed using standard methods.

Histology

Methods for light and electron microscopy are described in Noakes et al. (1995b). Antibodies to collagens α3-5(IV), laminin-1, laminin β2, collagens I and VI, and neural cell adhesion molecule (N-CAM) were generated in our laboratory (Sanes et al., 1990; Miner and Sanes, 1994; Noakes et al., 1995a,b). Several antibodies were gifts of generous colleagues: antiperlecan (HK102 and HK84) from K. Kimata (Nagoya University, Nagoya, Japan) and M. Yamagata (National Institute for Basic Biology, Okazaki, Japan) (Kato et al., 1988), antilaminin β1 (5A2) from D. Abrahamson (University of Alabama at Birmingham) (Abrahamson et al., 1989), anti-integrin α6 from A. Chung (University of Pittsburgh, Pittsburgh, PA) (Bender et al., 1981), anti-integrin α2 (MA2) from S. Santoro (Washington University, St. Louis, MO) (Wu and Santoro, 1994), anti-integrin α3 from R. Hynes (Massachusetts Institute of Technology, Cambridge, MA) (De-Persio et al., 1995), anti-integrin α7 from S. Kaufman (University of Illinois, Urbana, IL) (Martin et al., 1996), and antitennasin (578) from M. Schachner (Swiss Federal Inst. of Technology, Zurich, Switzerland) (Gatchalian et al., 1989). Commercial sources for other antibodies were Southern Biotechnology Associates, Birmingham, AL (collagen α2IV), Chemicon Intl., Temecula, CA (laminin γ1), Collaborative Research, Inc., Waltham, MA (fibronectin), Novocastra, Newcastle upon Tyne, UK (dystroglycan), and Serotec Ltd., Oxford, U.K. (integrin α6).

Results

To mutate the collagen α3(IV) gene (Col4α3), we deleted the first three coding exons of the COOH-terminal noncollagenous (NCI) domain (Fig. 1 a). This mutation was chosen because the NCI domain is essential for assembly of a collagen IV network (Yurchenco and O’Rear, 1994; Ries et al., 1995; Zhou and Reeders, 1996) and because a similar mutation in the human COL4A5 gene leads to a severe form of Alport syndrome (Tryggvason, 1996). The targeting vector was transferred to embryonic stem (ES) cells by electroporation, homologous recombinants were identified, and three independently derived ES cell clones generated germline chimeras after injection into mouse blastocysts. Heterozygotes displayed no detectable abnormalities and produced homozygotes at the expected Mendelian frequency. Southern analysis of genomic DNA from homozygotes confirmed disruption of the Col4α3 gene (Fig. 1 b). As expected, no immunoreactivity was detected in any tissue with antisera to the NCI domain of collagen α3(IV) (see below). Probes that recognize the NH2-terminal portion of the protein or the 5′ end of the mRNA are unavailable for mouse, so we do not know whether truncated protein is produced. Studies of other collagens have shown, however, that any collagen chains

Figure 1. Mutation of the Col4α3 gene. (a) Structure of the collagen α3(IV) protein and targeting vector, and the predicted product of homologous recombination. The protein contains a central triple helical collagenous region and a COOH-terminal noncollagenous (NCI) domain, which is essential for BL assembly. Three exons of the NCI domain were deleted in the targeting vector. (b) Southern blot analysis of PstI-digested genomic DNA. The probe, which was from outside the short arm, is indicated in a. The 3.9-kb band present in wild-type mice was altered to 2.9 kb in the mutant.
unable to assemble into matrix would be rapidly degraded (Prockop, 1992).

Renal Failure in Collagen α3(IV) Mutant Mice

Homozygous Col4a3 mutants were externally normal at birth and for ~2 mo thereafter. At 2–3 mo of age, however, most homozygotes began to lose weight and became lethargic. Many died in the third postnatal month, and only ~5% lived longer than 4 mo. Based on the prominent glomerulonephritis in patient’s with Alport syndrome, we suspected that renal failure was largely responsible for the mutants’ phenotype. Indeed, mutant kidneys were shrunken, wrinkled, and discolored compared to those of heterozygous littermates at >P65 (Fig. 2, c and d). Histological confirmation of glomerulonephritis is detailed below. In contrast, kidneys were externally normal in ≤5-wk-old mutants (Fig. 2, a and b) and displayed only minor histological abnormalities (Fig. 2, e and f). Thus, the Col4a3 mutant resembles humans with Alport syndrome in displaying delayed onset renal disease.

To determine whether the renal abnormality was accompanied by impaired renal function, we measured urea and creatinine levels in blood and urine (Yager and Harrington, 1995). Urea and creatinine are produced in tissues, dissolved in blood, and passed nonselectively through the glomerular filter. Decreased glomerular function thereby leads to increased levels of both metabolites in the serum. In control mice, blood urea nitrogen (BUN) and creatinine levels changed little between postnatal days (P)20 and 120 (Fig. 3, a and b). Levels of both compounds were normal in mutants until ~P60 and then increased.

Figure 2. Morphology and histology of collagen α3(IV)–deficient kidneys. (a–d) Kidneys from homozygous mutant mice (b and d) and littermate controls (a and c) at P36 (a and b) and P103 (c and d). Mutant kidneys are externally normal at P36 but shrunken and mottled at P103. (e–j) Periodic acid Schiff–stained sections from mutant (f, h, and j) and control (e, g, and i) kidneys at P36 (e and f) and P79 (g–j). Renal histology is nearly normal at P36, but glomerulosclerosis (h, arrowheads in j), glomerular crescents (C), an expanded interstitium, proteinaceous glomerular deposits (arrow in h), tubular deposits (j), and tubular atrophy are evident at P79. Bar in j: (e–h) 50 μm; (i and j) 100 μm.
during the next month, indicating decreased filtration. Moreover, urinary volume was increased and urea nitrogen and creatinine concentrations in urine were decreased relative to controls (data not shown), which may indicate failure to concentrate the urine (a tubular function) as well as impaired filtration (a glomerular function; Yager and Harrington, 1995). Interestingly, a minority of mutants maintained normal levels of urea and creatinine in their blood as late as P100 (Fig. 3, a and b), and their kidneys showed correspondingly mild pathology (data not shown). In general, the mice with the most severe histological abnormalities displayed the most severe uremia and proteinuria. This correlation was evident both as a function of age and when comparing mice at a single age. Thus, although loss of collagen α3(IV) always led to renal failure, the rate of appearance and the severity of the defect were variable.

Because the glomerular filter is freely permeable to urea and creatinine, their levels primarily reflect filtration capacity but not the integrity of the filter. To test the latter, we analyzed urine for the presence of protein, which is normally excluded from the urinary space by the glomerular BL and the cells that abut it. Levels of urinary protein were normalized to urinary creatinine to account for potential differences in the degree to which samples had been concentrated by the kidney. Until P40, mutant protein/creatinine ratios were only slightly higher than controls, but at later ages they were elevated from 2- to >20-fold (Fig. 3 c). Oddly, however, hematuria, a cardinal sign of Alport and other glomerulonephritides, was not evident in the Col4a3 mutant. Therefore, to confirm that proteinuria reflected glomerular failure, we analyzed urinary protein by gel electrophoresis. When intact, the glomerular filter acts as a barrier to large proteins, such as albumin, whereas the predominant urinary proteins are of lower molecular weight in rare cases of tubular failure to resorb protein (Carlson and Harrington, 1993). As expected, the major protein in mutant urine was albumin (Fig. 3 d), confirming that the glomerular filter had been breached.

**Molecular Consequences of Collagen α3(IV) Deficiency**

Collagens α3–5(IV) are present in renal BLs soon after birth (Miner and Sanes, 1994), yet we were unable to detect renal defects in the Col4a3 mutant until after P40. Molecular alterations that precede overt pathology might provide insights into the role of collagen α3(IV) in BL assembly, BL-cell interactions, and the pathogenesis of Alport syndrome. Accordingly, we stained kidneys from P15–30 mutants and littermate controls with a panel of antibodies to BL and plasma membrane components.

First, we assayed the collagen IV chains. As expected, collagen α3(IV) was prominent in the BLs of glomeruli and of most tubules in controls but was undetectable in mutant BLs (Fig. 4, a and b). Collagens α4 and α5(IV) were codistributed with collagen α3(IV) in controls but undetectable in mutants (Fig. 4, c and d, and Table I). In contrast, the collagen α1/α2(IV) chains were nearly absent from control glomerular BL, but readily detectable in the mutant (Fig. 4, e and f). Thus, disruption of the Col4a3 gene leads to alterations in the complement of collagen IV chains found in both glomerular and tubular BLs.

**Figure 3.** Analysis of serum and urine. (a) Creatinine concentration in serum. (b) BUN concentration. (c) Protein levels in urine, normalized for urinary creatinine to correct for differences in degree of urine concentration. Relative levels of urinary protein are similar in mutants and controls until ~P40, then rise many-fold in mutants; levels of serum creatinine and BUN do not rise appreciably in mutants until after P60. Blood and urine were collected from anesthetized mice immediately before sacrifice. Each point represents a single mouse. (d) SDS–gel electrophoresis reveals that the major urinary protein in mutants is albumin, indicative of a defective glomerular barrier.

Changes in collagen IV immunoreactivity could reflect alterations at any of several levels, from transcription to chain assembly. To begin to distinguish these alternatives, we used an RNase protection assay to determine the levels of collagen α1, α4, and α5(IV) mRNAs in control and mutant kidneys (Fig. 5). Collagen α1(IV) mRNA levels were similar in mutant and wild-type animals at P28–40, al-
though levels in mutants increased thereafter. In contrast, α4 and α5(IV) mRNAs were slightly elevated in mutants at all ages, indicating that the absence of these chains from mutant BLs reflects regulation at a posttranscriptional level.

Further immunohistochemical analysis revealed three unexpected changes in the composition of glomerular BL in the mutant. First, levels of a heparan sulfate proteoglycan, perlecan (Couchman et al., 1993), were greatly increased in mutant glomerular BL; in controls, perlecan was present but concentrated in the mesangium (Fig. 4, g and h). Similar results were obtained with two independently isolated antibodies (see Materials and Methods), indicating that this alteration was more likely to reflect an increase in the level of perlecan than increased accessibility of an epitope. Second, fibronectin was abundant in the mesangium of control glomeruli, but absent from the BL of peripheral capillary loops (Laitinen et al., 1991). In mutants, in contrast, fibronectin was present at similar levels in BL and mesangium (Fig. 4, i and j). Similarly, collagen VI was restricted to mesangium in control glomeruli (Kashtan and Kim, 1992) but was also detectable in the glomerular BL of mutants (data not shown).

In contrast to these alterations, the distribution of the major noncollagenous proteins of BLs, laminin, and entactin did not differ detectably between control and mutant kidneys (Fig. 4, k and l, and Table I). Moreover, the subunit composition of laminin was similar in controls (Sanes et al., 1990; Miner and Sanes, 1994) and mutants: tubular

### Table I. Distribution of Matrix and Membrane Antigens in the Kidneys of Control and Col4α3 Mutant Mice

<table>
<thead>
<tr>
<th>Component</th>
<th>G</th>
<th>M</th>
<th>T</th>
<th>I</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal lamina</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagen α1/2(IV)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>α3(IV)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>α4(IV)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Collagen α5(IV)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Laminin-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>β1</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>β2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>γ1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Entactin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Perlecan</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Matrix</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagen I</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tenascin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Membrane</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrin α2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>α3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>α6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>α7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dystroglycan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NCAM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

G, glomerular BL or abutting cell membranes; M, mesangium; T, tubular BL or abutting membranes; I, interstitium; C, glomerular crescents. For each set of three entries, the first is from P15–66 control, the second from P30–35 mutant, and the third from P66–75 mutant. Crescents were present only in mutants at >P30. + or + denotes presence or absence of staining, respectively; * denotes dim staining; + denotes that only a subset was +. Note that integrin α2 and dystroglycan are present in developing nephrons (Wu and Santoro, 1993; Durbeej et al., 1995).
and glomerular BLs were rich in the γ1 chain, tubular BL contained β1 but no β2 chain, and glomerular BL contained β2 but little β1 chain (Table 1). Likewise, both mutant and control glomerular BL were rich in the recently described laminin α5 chain (Miner et al., 1995), as revealed with an antiserum to a recombinant α5 fragment (Miner, J.H., and J.R. Sanes, manuscript in preparation). In addition, the distribution and apparent levels of major cell surface receptors for BL components (Korhonen et al., 1990; Patey et al., 1994; Durbeej et al., 1995) were similar in mutants and controls; components examined included the collagen IV– and laminin-binding integrin subunits α2, α3, α6, and α7 and the nonintegrin laminin receptor, dystroglycan (Table 1). Thus, the alterations in the molecular architecture of mutant glomeruli are profound but selective.

Finally, we examined early postnatal kidneys in which nephrons were still forming. In the developing wild-type nephron, glomerular BL is initially rich in collagen α1 and α2(IV) and laminin β1, but these chains are joined by and eventually replaced by the collagen α3–5(IV) and laminin β2 chains, respectively, as glomerulogenesis proceeds. Tubular BL is α1,2(IV)-positive and mostly α3–5(IV)-negative at birth, but α3–5(IV) appears in a subset of tubules during the first postnatal weeks. However, in contrast to glomerular BL, tubular BL remains strongly α1,2(IV)-positive into adulthood (Miner and Sanes, 1994). Based on these patterns of expression, it seemed possible that development of tubules or glomeruli might be perturbed or delayed in the mutant. However, no defects were detected in mutant P3 kidneys, which contain glomeruli and tubules at various stages of development (Fig. 4, m and n). Moreover, the molecular transition from laminin β1 to β2 occurred on schedule in mutant glomerular BL (not shown). Thus, the appearance of the collagen α3–5(IV) chains accompanies but is not required for key events in the development of the nephron.

Pathological Consequences of Collagen α3–5(IV) Loss

At P40, a few glomeruli in mutant kidneys were subtly abnormal by conventional histological criteria: they contained restricted segments of thickened Bowman's capsule (crescents) and/or patches of thickened, closed capillary loops (segmental glomerulosclerosis). Both the number of glomeruli affected and the severity of the defects increased during the subsequent 4–6 wk. During the same period, some tubules atrophied and others dilated, cells and extracellular matrix accumulated in interstitial spaces between tubules, and many tubules and glomerular capillaries became filled with hyalin deposits (Figs. 2, g–j, and 6, a and b). By P65, mutant kidneys displayed many signs of chronic glomerulonephritis (Kashtan and Michael, 1993; Kashtan et al., 1994).

Although several distinct human glomerulonephritides are similar by light microscopic criteria, glomeruli in Alport syndrome display a distinctive ultrastructural sign: the presence of a thickened, filamentous BL, which has been referred to as a “basket weave” (Kashtan and Michael, 1993; Kashtan et al., 1994). Numerous segments of glomerular BL in Col4a3 mutant mice displayed a basket-weave appearance by P60 (Fig. 7). Although its etiology is not understood, this ultrastructural alteration provides strong evidence that the structural consequences of collagen α3–5(IV) deficiency are similar in mice and humans.

The sclerotic glomeruli and expanded tubulointerstitial spaces that appeared in the mutant contained increased levels of several matrix proteins. Glomeruli accumulated collagen α1/2(IV), laminins β1, β2, and γ1, entactin, and perlecan. Expanded interstitial spaces accumulated collagen V and tenasin, which were sparse in normal kidney (Kashtan and Kim, 1992; Truong et al., 1994), as well as collagens I and VI and fibronectin, which were present in both control and mutant interstitia (Fig. 6, a–d, and Table 1). Consistent with the expansion of the collagen α1(IV)-rich matrix, the abundance of collagen α1(IV) RNA increased severalfold in mutant kidney between ~P40 and P99 (Fig. 5 b). On the other hand, no significant changes in the composition of mutant BL in nonsclerotic glomeruli were detected by immunohistochemistry between P15 and the time that renal disease became severe (Table 1).

A surprising observation was the accumulation of two membrane-associated adhesive proteins, N-CAM and integrin α6, in the mutant renal cortex. N-CAM was confined to Bowman's capsule in normal kidney, as reported...
previously (Klein et al., 1988), but was enriched in the cellular crescents that formed during the initial stage of glomerulonephritis (Fig. 6, e and f). The presence of N-CAM on these cells, along with their localization, suggests that they were derived from the parietal epithelial cells that comprise Bowman’s capsule. Moreover, the paucity of N-CAM in normal kidney and its expression in crescents provided a useful marker for the relatively rare abnormal glomeruli at early stages (Fig. 6 i). Integrin α6 was present at low levels on the basal side of all tubules in control kidney (Korhonen et al., 1990; Patey et al., 1994) but accumulated to high levels on the basolateral membranes of some tubules in the mutant (Fig. 6, g and h). Perhaps physiological changes that lead to or accompany tubular alterations in chronic nephritis cause up-regulation of this integrin subunit. Finally, some of the cells in the interstitial spaces in the mutant kidneys were labeled by antibodies to integrin α6 and N-CAM (Fig. 6, e–h). Double-labeling experiments revealed that the integrin α6– and N-CAM–positive interstitial cells were distinct (data not shown), suggesting the accumulation of at least two different populations of cells in the interstitium.

**Extrarenal Consequences of Collagen α3–5(IV) Loss**

Collagen α3(IV) is present in several nonrenal BLs, including those of cochlea, testis, lung, and skeletal neuromuscular junction. Immunohistochemical analyses of some of these tissues revealed two distinct patterns of collagen IV chain accumulation in the Col4a3 mutant. First, alveo-
Figure 7. Electron micrographs of glomerular BL in P66 control (a) and mutant (b) kidneys. The basket-weaving that characterizes glomerular BL in humans with Alport syndrome is apparent in the mutant. Arrows indicate glomerular BL. RBC, red blood cell. Bar, 0.5 μm.

No alterations in gross structure were detected in extrarenal tissues by conventional histological methods, nor were their functions detectably impaired. Matings of Col4a3 mutant homozygous males and females to wild-type mice or to each other gave rise to litters of normal size. We observed no impairment of pulmonary function in Col4a3 mutants, despite the abundance of collagen α3−5(IV) RNA and protein in normal lung (Gunwar et al., 1991; Miner and Sanes, 1994). Initial ultrastructural and immunohistochemical analyses of neuromuscular junctions (see Noakes et al., 1995a, for methods) revealed no abnormalities; electrophysiological studies to seek subtle defects are in progress. Finally, since sensorineural deafness frequently accompanies Alport syndrome (Kashtan et al., 1994; Wester et al., 1995), we examined auditory function by recording auditory brainstem responses to clicks and tone pips (Colvin et al., 1996) from homozygotes and littermate controls. In 3 of 12 pairs of mice studied, auditory thresholds were significantly higher in the mutant than in the control. For the other nine mutants, however, thresholds and sensitivities were within the normal range. Importantly, auditory sensitivity was normal in mutants studied at P89 and P96, when renal pathology was already severe (Bohne, B.A., G.W. Harding, J.H. Miner, and J.R. Sanes, unpublished observations). These results suggest that cochlear manifestations of collagen α3(IV) loss might depend on strain-dependent modifier genes, as has been observed for several heritable forms of deafness in mice and humans (Li and Borg, 1991). We are now testing this possibility by backcrossing the Col4a3 mutant allele into various inbred backgrounds.

Discussion

Mutation of the Col4a3 gene in mice led to delayed-onset, progressive renal disease that includes decreased glomerular filtration (resulting in uremia) and increased glomerular permeability (resulting in proteinuria). By light microscopic criteria, the kidneys displayed glomerulosclerosis, tubular atrophy, and accumulation of interstitial cells and extracellular matrix. Electron microscopy revealed a characteristic basket-weave thickening and lamellation of the glomerular BL. In all of these respects, Col4a3 mutant mice resemble humans with Alport syndrome (Barker et al., 1990; Kashtan and Michael, 1993; Kashtan et al., 1994; Lemmink et al., 1994; Mochizuki et al., 1994; Antignac, 1995; Kawai et al., 1996; Tryggvason, 1996).
The Col4a3 mutant has permitted us to seek molecular changes that precede, and might therefore contribute to, renal pathology. We found that loss of collagen α3(IV) led to several changes in the composition of glomerular BL, some of which were apparent by P15, weeks before histological or physiological changes were observed. These include absence of collagens α4(IV) and α5(IV) and increased levels of collagens α1,2(IV), fibronectin, perlecan, and collagen VI. Some of these alterations have been noted previously in human Alport syndrome (Kleppel et al., 1987; Kashtan and Kim, 1992; Gubler et al., 1995), but it has not been clear whether their appearance preceded clinical manifestations of disease. Our observation that the molecular composition of glomerular BL is altered in numerous ways before renal function is detectably impaired raises the possibility that these changes, as well as loss of collagen α3–5(IV) per se, contribute to renal failure in Alport syndrome.

The first histological abnormality observed was the appearance of glomerular crescents, visible in a small percentage of glomeruli by P30. Such crescents are not common in Alport syndrome but have been described repeatedly (see Gregory and Atkins, 1993 for references). N-CAM, which is normally confined to Bowman’s capsule in adult kidney (Klein et al., 1988), was present on the cells that formed the crescents, consistent with their apparent derivation from the parietal epithelium of Bowman’s capsule. Thus, N-CAM may serve as a useful early marker of compromised glomeruli.

Starting at around P60, levels of serum creatinine and blood urea nitrogen began to increase. These changes signaled a critical decrease in glomerular filtration, which became progressively more severe, culminating in renal failure and death. Histologically, glomerular BL acquired a basket-weave appearance, glomeruli became sclerotic, and the N-CAM–positive crescentic cells were replaced by deposits of matrix. The occlusion of Bowman’s space and of glomerular capillaries and the fragmentation of glomerular BL are presumably the proximate causes of reduced filtration rate and selectivity, respectively. Tubular involvement was also apparent in late stages of the disease. Many tubules atrophied, while others became dilated with protein deposits. Integrin α6 levels increased markedly in a subset of tubules. Interstitial spaces between tubules expanded and became filled with cells and extracellular matrix. In human Alport syndrome, interstitial fibrosis predominates, but cellular accumulation has also been described (Kashtan et al., 1994).

This sequence of events leads to a speculative model of how the Col4a3 mutation leads to renal disease. We propose that in glomerular BL, the absence of full-length collagen α3(IV) prevents the assembly of the collagen α4 and α5(IV) chains into a collagen IV network, leading to the degradation of these chains (Prockop, 1992). The collagen α1,2(IV) network that appears during glomerular development remains as part of the mature glomerular BL, thereby compensating structurally for loss of α3–5(IV). However, fundamental differences between collagen α1,2(IV) and α3–5(IV) networks lead to accumulation of supranormal levels of perlecan and ectopic fibronectin and collagen VI in the glomerular BL. The changed BL composition results in glomerulopathy. The tubular involvement we observed may be a nonspecific response to chronic glomerular disease or may result from the lack of the collagen α3–5(IV) chains in the subset of proximal and distal tubular BLs, where they are normally found. Another possibility, suggested by the accumulation of cells in the interstitium, is that an immune response might contribute to progression of the disease.

The glomerular structure and function in the Col4a3 mutant contrast greatly with those in a mutant that lacks another major component of glomerular BL, laminin β2 (Noakes et al., 1995a,b). Perinatally, glomerular BL undergoes a developmental transition from a preponderance of laminin β1 and collagen α1/2(IV) to a preponderance of laminin β2 and collagen α3–5(IV) (Miner and Sanes, 1994). In the Col4a3 mutant, the α1 and α2 chains compensated for the loss of α3–5(IV), but the laminin β1–β2 transition clearly occurred. We showed previously that laminin β1 levels remain high in the glomerular BL of laminin β2 mutants but that the transition in collagen IV chains occurs on schedule (Noakes et al., 1995b). Together, these results demonstrate that the isoform composition of the two major macromolecular networks of the BL, the collagens IV and the laminins, are regulated independently. Moreover, the mutant phenotypes are extremely different. The laminin β2 mutant exhibits massive proteinuria at 1–2 wk of age, but this occurs in the absence of severe histological change in the kidney. This pattern of impaired function with minimally altered structure is reminiscent of minimal change nephrotic syndrome in humans (Olson, 1992). In contrast, the Col4a3 mutant exhibits delayed-onset renal disease characterized by glomerular structural abnormalities and interstitial fibrosis; this is strikingly similar to the pathology of human Alport syndrome.

The distinct phenotypes of laminin and collagen IV mutations indicate that these molecules play distinct roles in the glomerulus. We suggest that laminin β2 is a signaling molecule that influences the maturation or maintenance of the podocyte. In its absence, podocyte differentiation is impaired, and the glomerular filtration barrier does not mature properly. In contrast, the collagen α3–5(IV) chains appear to be important for the structural integrity of the mature glomerular BL. Thus, loss of the collagen chains leads to a significant change in the molecular architecture and to the eventual breakdown of the glomerular BL.

There is, however, an alternative view of both mutant phenotypes: perhaps it is neither the absence of the normal adult isoform nor the persistence of the fetal isoform that leads to renal dysfunction, but rather the generation of an incompatible “mismatch” between laminins and collagens IV. Thus, in the laminin β2 mutant, a fetal β1-containing laminin network is associated with the normal adult collagen α3–5(IV) network, whereas in the collagen α3(IV) mutant, a fetal collagen α1/2(IV) network coexists with the normal β2-containing laminin network. If such incompatibility leads to disease, we would expect that double mutants lacking both laminin β2 and collagen α3(IV), which would have a fully fetal (laminin β1– and collagen α1/2(IV)–containing) glomerular BL, might have a less severe phenotype than either single mutant. In contrast, if laminin β2 and the collagen α3–5(IV) chains play distinct roles, then the double mutants would exhibit a more se-
were phenotype than the single mutants. We are currently testing these ideas.

We thank M. Nichol and J. Mudd for generation of chimeras; M. Nichol for superb management of the animal facility; J. Cunningham, M. Elam, B. Klocke, S. King, and J. Merlie Jr. for assistance; A. Nagy for RI ES cells; Drs. D. Abrahamson, A. Chung, R. Hynes, S. Kaufman, K. Kimata, M. Schachner, M. Yamagata, A. Pearlman, and S. Santoro, for antibodies; S. Gluck for comments on the manuscript; and the late J.P. Merlie for valuable advice during the early stages of this work.

This work was supported by grants from the National Institutes of Health and the Muscular Dystrophy Association to J.R. Sanes. J.H. Miner was supported by a Damon Runyon-Walter Winchell Cancer Research Fund Fellowship.

Received for publication 8 August 1996 and in revised form 17 September 1996.

References


